Drawing for MICRODUR

USPTO serial 77869355

MICRODUR

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
FIRST, VIVIAN M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MICRODUR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Diane M. Lambillotte

DIANE M. LAMBILLOTTE ARNOLD & PORTER LLP777 S FIGUEROA ST FL 44LOS ANGELES, CA 90017-5800UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and/or veterinary preparations for the treatment of pain and wounds, pain relief and pain management, inflammation, traumas, surgery and emergencies, addictions, aging and age-related disorders, allergy/immunology, cardiovascular diseases, dental and gum diseases, skin diseases, nutritional and dietary diseases, diseases of the endocrinological system and pancreatic diseases, diabetes, obesity, diseases and afflictions of the gastrointestional system, diseases of the blood, infectious diseases, sepsis, neurological diseases and disorders of the central nervous system, psychiatric related diseases and disorders, nephrological diseases, obstetrical and gynecological diseases, occupational diseases and afflictions, cancer, ophthalmological diseases, diseases and afflictions affecting the bones, joints, cartilage material and muscles, respiratory diseases, psychotropic preparations, pulmonological diseases, disorders and afflictions, rheumatism, urological diseases and afflictions, hormonal disorders, muscular disorders, cough, vertigo, nausea, vomiting and migraine, and reproductive system disease and disorders; pharmaceutical and veterinary drug delivery systems, namely, polymer-based drug delivery formulations used with various medications for sustained release of medication into the body; injectable drug delivery solutions that facilitate delivery of a wide range of pharmaceuticals; medical and/or veterinary apparatus, namely, microspheres, microcapsules, and microparticles, all composed of non-living biodegradable polymers for use in drug delivery that facilitate delivery of a wide range of pharmaceuticalsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 6, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 6, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 2, 2010NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 7, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 7, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 31, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 31, 2010ALIEASSIGNED TO LIE—
Jul 19, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 16, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 14, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 14, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 17, 2010GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2010GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 17, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2010DOCKASSIGNED TO EXAMINER—
Nov 17, 2009MPMKNOTICE OF PSEUDO MARK MAILED—
Nov 16, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 13, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance